We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The FDA has granted Priority Review for this application and assigned a Prescription Drug User Fee Act (PDUFA) action date of March 26, 2025. Also Read: GSK Sues Moderna Alleging mRNA Vaccine ...

GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

AstraZeneca and GlaxoSmithKline produce some of the most ... Greening the brand-name products will allow pharmaceutical companies to bring them back under patent protection and effectively kill ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn ... reflecting strong performance of new products and the investment we've put ...